Karyopharm Therapeutics Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Karyopharm Therapeutics stock.
View analyst ratings for Karyopharm Therapeutics or view top-rated stocks.

Wall Street analysts have given Karyopharm Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Karyopharm Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Karyopharm Therapeutics.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its earnings results on Sunday, May, 2nd. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.71) by $0.06. The business earned $23.26 million during the quarter, compared to analyst estimates of $26.50 million. Karyopharm Therapeutics had a negative trailing twelve-month return on equity of 357.73% and a negative net margin of 177.34%.
View Karyopharm Therapeutics' earnings history.

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KPTI stock has decreased by 51.4% and is now trading at $10.32.
View which stocks have been most impacted by COVID-19.

8 brokerages have issued 1-year price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $15.00 to $41.00. On average, they expect Karyopharm Therapeutics' share price to reach $27.75 in the next year. This suggests a possible upside of 168.9% from the stock's current price.
View analysts' price targets for Karyopharm Therapeutics or view top-rated stocks among Wall Street analysts.

31 employees have rated Karyopharm Therapeutics CEO Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among Karyopharm Therapeutics' employees.

Some companies that are related to Karyopharm Therapeutics include Cassava Sciences (SAVA), PTC Therapeutics (PTCT), Insmed (INSM), IGM Biosciences (IGMS), Rocket Pharmaceuticals (RCKT), Nuvation Bio (NUVB), Taro Pharmaceutical Industries (TARO), Amicus Therapeutics (FOLD), MorphoSys (MOR), Cryoport (CYRX), Pacira BioSciences (PCRX), Global Blood Therapeutics (GBT), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH) and Axsome Therapeutics (AXSM).
View all of KPTI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.32%), Palo Alto Investors LP (7.14%), Morgan Stanley (2.26%), Goldman Sachs Group Inc. (1.61%), C WorldWide Group Holding A S (1.60%) and Geode Capital Management LLC (1.53%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, Sharon Shacham and Tanya Lewis.
View institutional ownership trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, D. E. Shaw & Co. Inc., Price T Rowe Associates Inc. MD, Allianz Asset Management GmbH, Nuveen Asset Management LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Sharon Shacham, and Tanya Lewis.
View insider buying and selling activity for Karyopharm Therapeutics or view top insider-selling stocks.

KPTI stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Compagnie Lombard Odier SCmA, C WorldWide Group Holding A S, Citigroup Inc., BlackRock Inc., Hennion & Walsh Asset Management Inc., Rafferty Asset Management LLC, and Schonfeld Strategic Advisors LLC. Company insiders that have bought Karyopharm Therapeutics stock in the last two years include Garen G Bohlin, Jatin Shah, and John Demaree.
View insider buying and selling activity for Karyopharm Therapeutics or or view top insider-buying stocks.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KPTI stock can currently be purchased for approximately $10.32.

Karyopharm Therapeutics has a market capitalization of $774.93 million and generates $108.08 million in revenue each year. The company earns $-196,270,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis.

Karyopharm Therapeutics employs 432 workers across the globe.

The official website for Karyopharm Therapeutics is www.karyopharm.com.

Karyopharm Therapeutics is headquartered at 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]